Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts

Multiple myeloma is a fatal hematological malignancy with high rates of drug resistance and relapse. Vorinostat, a histone deacetylase inhibitor, has shown promise in enhancing efficacy when combined with current myeloma therapies. In this study, temporal changes of critical proteins and cell prolif...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanavati, Charvi, Ruszaj, Donna, Mager, Donald E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702904/
https://www.ncbi.nlm.nih.gov/pubmed/29045072
http://dx.doi.org/10.1002/psp4.12246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702904/
https://www.ncbi.nlm.nih.gov/pubmed/29045072
http://dx.doi.org/10.1002/psp4.12246

Ejemplares similares